The purpose of this research study is to compare the effects (good and bad) on subjects
and their cancer using standard chemotherapy in combination with hypofractionated proton
radiation therapy. Hypofractionation is a technique that delivers higher daily doses of
radiation over a shorter period of time.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT01770418.
Locations matching your search criteria
United States
Maryland
Baltimore
Maryland Proton Treatment CenterStatus: Active
Contact: Ashley D. Hargrove
Phone: 410-369-5355
Conventional fractionated photon-based radiotherapy to 60-63 Gy at 1.8-2 Gy/fraction with
concurrent chemotherapy remains the standard treatment practice in patients with stage
III non-small cell lung carcinoma (NSCLC) with local control rates of approximately 50%
and a median overall survival of just 18 months.Unfortunately, even the standard
treatment has significant toxicity with approximately 40% of patients developing grade 3
or higher acute toxicities in the RTOG 9410 study.1 These outcomes are poor and more
effective treatment regimens are needed.
Higher doses of radiation have been hypothesized to improve local control in patients
with stage III NSCLC. This is expected to translate into better overall survival.Given
the significant improvements in outcome in patients receiving hypofractionation for stage
I NSCLC, perhaps similar gains could be achieved if hypofractionated radiotherapy could
be safely delivered to stage II-III NSCLC with concurrent chemotherapy. Hypofractionated
radiotherapy may offer improvement in local control compared with conventional
fractionation that may translate into improved overall survival. Furthermore,
hypofractionation will shorten the time interval during which patients are receiving less
aggressive chemotherapy. Proton therapy is a highly conformal radiotherapy technique that
takes advantage of the proton's characteristic Bragg Peak, resulting in significant
reductions in the exit dose of the treatment beam. Thus, proton therapy can substantially
reduce the dose to critical structures even compared with IMRT.
This study will investigate the safety and efficacy of delivering hypofractionated proton
therapy with concurrent chemotherapy in patients with stage II-III NSCLC
Lead OrganizationProton Collaborative Group